Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- Nodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone LymphomaWaldenström MacroglobulinemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueRecurrent Adult Burkitt LymphomaRecurrent Adult Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT00073918
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00074165
- Locations
- 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
- Conditions
- First Posted Date
- 2003-12-10
- Last Posted Date
- 2013-07-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 27
- Registration Number
- NCT00003811
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Boston Floating Hospital Infants and Children, Boston, Massachusetts, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 184
- Registration Number
- NCT00002836
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 7
- Registration Number
- NCT00072280
- Locations
- 🇺🇸
Kosair Children's Hospital, Louisville, Kentucky, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Spectrum Health Hospital - Butterworth Campus, Grand Rapids, Michigan, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 94
- Registration Number
- NCT00003141
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT00072384
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 78
- Registration Number
- NCT00072527
- Locations
- 🇺🇸
McDonough District Hospital, Macomb, Illinois, United States
🇺🇸Hudner Oncology Center at Saint Anne's Hospital, Fall River, Massachusetts, United States
🇺🇸Saint Luke's Hospital, Chesterfield, Missouri, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 59
- Registration Number
- NCT00005964
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 640
- Registration Number
- NCT00003190
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.